Hong Kong Agreement on IPR and Access to Medicines: Public Health - PowerPoint PPT Presentation

1 / 18
About This Presentation
Title:

Hong Kong Agreement on IPR and Access to Medicines: Public Health

Description:

R & D Spending 10 major pharmaceutical companies, 2001. Source: Moses, Z. (2002). The Pharmaceutical Industry Paradox. Reuters Business Insight ... – PowerPoint PPT presentation

Number of Views:55
Avg rating:3.0/5.0
Slides: 19
Provided by: JCraigP9
Category:

less

Transcript and Presenter's Notes

Title: Hong Kong Agreement on IPR and Access to Medicines: Public Health


1
Hong Kong Agreement on IPR and Access to
Medicines Public Health Human Rights
Considerations
  • J. Craig Phillips
  • LLM, MSN, ARNP, BC, ACRN
  • Florida International University

2
Codification of Health as a Human Right
  • International Human Rights Instruments
  • Universal Declaration of Human Rights
  • International Covenant on Economic, Social, and
    Cultural Rights
  • International Covenant on Civil and Political
    Rights its Optional Protocols
  • Constitution of the World Health Organization

3
Codification of Health as a Human Right
  • Inter-American System of Human Rights
  • Additional Protocol of the American Convention on
    Human Rights in the Area of Economic, Social, and
    Cultural Rights (Protocol of San Salvador)
  • American Declaration of the Rights and Duties of
    Man

4
Public Health Goals Access to Medicines Human
Rights Context
  • Rapid effective response to Public Health Needs
    Crises
  • Quality meds at affordable prices
  • Effective competition multiplicity of suppliers
  • Wide range of Rx to meet basic health needs of
    the population
  • Equality of opportunities for countries in need

5
Where are the Worlds Medicines?
6
Research Development
  • Pharmaceutical R D the 50/50 split
  • Public Funding
  • High-income Transition countries 47
  • Low- Middle-income countries 3
  • Private Funding
  • Pharmaceutical Industry 42
  • Private not-for-profit funding 8

Source WHO (2004). The World Medicines Situation
7
Why protect patents?
  • Pros
  • Innovation critical to new drugs development
  • Allows prices to be set by what the market will
    bear
  • Cons
  • Actual cost of new drugs
  • Neglect of diseases effecting worlds poor
  • High-income countries, where access inhibited by
    high prices

8
R D Spending 10 major pharmaceutical
companies, 2001
Source Moses, Z. (2002). The Pharmaceutical
Industry Paradox. Reuters Business Insight
9
What medicines are being developed?
  • Drugs development driven by market forces, not by
    health needs indicators
  • 10-20 of pharmaceutical R D used for 90 of
    the worlds disease burden
  • Examples
  • Newest class of antimycobacterial (TB) medication
    is 20 years old
  • Neglected Diseases Sleeping sickness,
    leishmaniasis, and Chagas disease

10
Pharmaceutical Spending
  • 1.4 World GDP Pharmaceuticals
  • High-income countries spend 80
  • Middle-income countries spend 19
  • Low-income countries spend 2.4
  • Highest expenditure increases occur in High-
    Middle-income countries

11
Access to Essential Medicines
  • 1.3 2.1 billion people without access
  • Africa and India worst effected
  • 10 of the Americas without access
  • Factors that can increase affordability
  • Generic competition
  • Differential pricing
  • Bulk purchasing
  • Compulsory licensing

12
The Access Framework
Source WHO (2000)
13
Rational Use of Medicines
  • Appropriate prescribing practices
  • Avoid overuse of unnecessary meds
  • Evidence-based diagnostic treatment guidelines
  • Monitoring regulation of medicines

14
Irrational medicines use
  • Too many medicines prescribed per patient
    (polypharmacy)
  • Injections used oral forms more appropriate
  • Antimicrobial medicines prescribed in inadequate
    dose duration or antibiotics prescribed for
    non-bacterial infections, thereby contributing to
    the growing problem of antimicrobial resistance
  • Prescriptions do not follow clinical guidelines
  • Patients self-medicate inappropriately or do not
    adhere to prescribed treatment.

15
Public Health Considerations
  • What constitutes a national emergency?
  • Botswana a case example
  • Population 1,640,115
  • Median age 29
  • Life expectancy 33.87 years
  • HIV/AIDS-adult prevalence 37.3
  • People living with HIV disease 350,000
  • GDP per capita - 10,100
  • Nations response to HIV disease

16
BotswanasAntiretroviral Program
  • Collaborative effort between Ministry of Health,
    Merck, Gates Foundation
  • Eligibility for ART program
  • Batswana with current Omang card
  • HIV antibody test positive
  • CD4 cell count 200 or less (CDC defined AIDS)

17
Conclusions
  • International law holds Governments accountable
    for Human Rights
  • Multinational Corporations are not governed by
    these international treaty agreements
  • Public Health goals require commitment of
    multiple actors governments, corporations, and
    private citizens

18
  • One of the greatest diseases is to be nobody to
    anybody
  • Mother Teresa
Write a Comment
User Comments (0)
About PowerShow.com